- Home
- TRIB vs REVB Comparison
TRIB vs REVB Comparison
Compare TRIB & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIB
- REVB
- Stock Information
- Founded
- TRIB 1992
- REVB 2020
- Country
- TRIB Ireland
- REVB United States
- Employees
- TRIB N/A
- REVB N/A
- Industry
- TRIB Biotechnology: In Vitro & In Vivo Diagnostic Substances
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- TRIB Health Care
- REVB Health Care
- Exchange
- TRIB Nasdaq
- REVB Nasdaq
- Market Cap
- TRIB 5.4M
- REVB 4.4M
- IPO Year
- TRIB N/A
- REVB N/A
- Fundamental
- Price
- TRIB $1.11
- REVB $2.84
- Analyst Decision
- TRIB
- REVB
- Analyst Count
- TRIB 0
- REVB 0
- Target Price
- TRIB N/A
- REVB N/A
- AVG Volume (30 Days)
- TRIB 13.5M
- REVB 81.2K
- Earning Date
- TRIB 11-14-2025
- REVB 11-07-2025
- Dividend Yield
- TRIB N/A
- REVB N/A
- EPS Growth
- TRIB N/A
- REVB N/A
- EPS
- TRIB N/A
- REVB N/A
- Revenue
- TRIB $61,555,000.00
- REVB N/A
- Revenue This Year
- TRIB $13.51
- REVB N/A
- Revenue Next Year
- TRIB $13.14
- REVB N/A
- P/E Ratio
- TRIB N/A
- REVB N/A
- Revenue Growth
- TRIB 8.31
- REVB N/A
- 52 Week Low
- TRIB $0.48
- REVB $2.11
- 52 Week High
- TRIB $3.44
- REVB $60.48
- Technical
- Relative Strength Index (RSI)
- TRIB 45.04
- REVB 55.04
- Support Level
- TRIB $1.42
- REVB $2.65
- Resistance Level
- TRIB $1.58
- REVB $2.88
- Average True Range (ATR)
- TRIB 0.15
- REVB 0.20
- MACD
- TRIB -0.07
- REVB 0.03
- Stochastic Oscillator
- TRIB 2.80
- REVB 81.98
About TRIB Trinity Biotech plc
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).